Indian Journal of Pathology and Microbiology
Home About us Instructions Submission Subscribe Advertise Contact e-Alerts Ahead Of Print Login 
Users Online: 9379
Print this page  Email this page Bookmark this page Small font sizeDefault font sizeIncrease font size
Year : 2011  |  Volume : 54  |  Issue : 1  |  Page : 117-120

JAK2-positive Philadelphia-negative myeloproliferative neoplasms

Department of Pathology, Dr. Ram Manohar Lohia Hospital, PGIMER, New Delhi, India

Correspondence Address:
Anjali Sharma
Department of Pathology, Dr. Ram Manohar Lohia Hospital, PGIMER, New Delhi
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0377-4929.77355

Rights and Permissions

The recent discovery of the JAK2 mutations has rekindled interest in the approach to classic BCR/ABL-negative myeloproliferative neoplasms (MPNs) in terms of both diagnostic evaluation and treatment. However, additional clinical, laboratory and histological parameters play a key role to allow diagnosis and subclassification, regardless of whether JAK2 V617F mutation is present or not. Here are two cases which incidentally presented with splenomegaly and moderate leukocytosis, and were diagnosed as MPN-primary myelofibrosis (PMF) in prefibrotic phase and polycythemia vera (PV), respectively, using revised World Health Organization (WHO) 2008 criteria.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded185    
    Comments [Add]    
    Cited by others 1    

Recommend this journal